307280 — Wonbiogen Co Income Statement
0.000.00%
- KR₩55bn
- KR₩40bn
- KR₩35bn
Annual income statement for Wonbiogen Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 17,721 | 26,748 | 29,615 | 30,440 | 35,244 |
| Cost of Revenue | |||||
| Gross Profit | 7,595 | 12,465 | 14,195 | 14,280 | 17,815 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15,681 | 21,797 | 22,492 | 24,230 | 27,480 |
| Operating Profit | 2,040 | 4,950 | 7,123 | 6,210 | 7,765 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -796 | 3,667 | 7,157 | 6,422 | 7,781 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -660 | 3,272 | 5,961 | 5,339 | 6,459 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -716 | 3,206 | 5,497 | 5,690 | 6,615 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -716 | 3,206 | 5,497 | 5,690 | 6,615 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -104 | 474 | 724 | 825 | 966 |
| Dividends per Share |